- CRISPR Therapeutics (NASDAQ:CRSP) slumps 11% premarket on average volume after reporting topline results from an open-label Phase 1 clinical trial, CARBON, evaluating allogeneic CAR T candidate CTX110 in patients with relapsed/refractory CD19+ B-cell blood cancers.
- Participants were infused with CTX110 after three days of lymphodepletion using chemo agents fludarabine and cyclophosphamide.
- The complete response rates at dose levels 2, 3 and 4 were 33% (n=1/3), 50% (n=2/4) and 100% (n=1/1), respectively. No response was observed at dose level one (n=0/3).
- On the safety front, no dose-limiting toxicities were reported for the dose levels 1-3, but the patient who showed a complete response after receiving dose level 4 died 52 days later after being hospitalized with febrile neutropenia that progressed to significant obtundation (lethargy, slow responses to stimulation) requiring intubation. The patient was subsequently found to have encephalitis.
https://seekingalpha.com/news/3624171-crispr-therapeutics-under-pressure-after-death-reported-in-early-stage-study-on-car-t
Wednesday, October 21, 2020
CRISPR Therapeutics under pressure after death in early-stage CAR T study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.